Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

L. Davila, Marco; Rivière, Isabelle; Wang, Xiuyan; Bartido, Shirley; H. Park, Jae; J. Curran, Kevin; S. Chung, Stephen; Stefanski, Jolanta; Bórquez-Ojeda, Oriana; Olszewska, Malgorzata; Qu, Jinrong; Wasielewska, Teresa; He, Qing; J. Fink, Mitsú; Shinglot, Himaly; Youssif, Maher; Satter, Mark; Wang, Yongzeng; Hosey, James; Quintanilla, Hilda; Halton, Elizabeth; Bernal, Yvette; Bouhassira, Diana; E. Arcila, Maria; Gönen, Mithat; J. Roboz, Gail; Maslak, P.; Douer, Dan; G. Frattini, Mark; Giralt, Sergio; Sadelain, Michel; J. Brentjens, Renier

doi:10.1126/scitranslmed.3008226

Public

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Published in Science Translational Medicine • Feb 19, 2014

Authors:

Marco L. Davila

Isabelle Rivière

Xiuyan Wang

Abstract

We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88%, which allowed us to transition most...

Subject

Medicine

Cytokine release syndrome

Blinatumomab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!